CSS
CYCN icon

Cubist Systematic Strategies’s Cyclerion Therapeutics CYCN Stock Holding History

Cubist Systematic Strategies’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-696
Closed -$24K – 3595
2021
Q4 		$24K Buy
+696
New +$32.9K ﹤0.01% 3367
2021
Q3 		– Sell
-854
Closed -$67K – 2990
2021
Q2 		$67K Buy
+854
New +$53.5K ﹤0.01% 2761
2020
Q1 		– Sell
-31
Closed -$2K – 2223
2019
Q4 		$2K Buy
+31
New +$2.9K ﹤0.01% 2386
2019
Q3 		– Sell
-528
Closed -$121K – 2261
2019
Q2 		$121K Buy
+528
New +$149K ﹤0.01% 2191

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Cubist Systematic Strategies's CYCN Position: Q1 2022 in Review

Cubist Systematic Strategies sold out of Cyclerion Therapeutics (CYCN) in Q1 2022, closing a stake of 696 shares — an estimated $24K sold.

Cubist Systematic Strategies first reported a position in CYCN in Q2 2019 and held it in 4 quarters. The position peaked at $121K in Q2 2019. 50 funds tracked by Wall St. Rank hold CYCN as of Q1 2022.

  • Cubist Systematic Strategies reported no remaining Cyclerion Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 696 Cyclerion Therapeutics shares in Q1 2022, an estimated $24K.
  • Cubist Systematic Strategies first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 4 quarters.
  • Cubist Systematic Strategies's Cyclerion Therapeutics position peaked at $121K in Q2 2019.
  • 50 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2022.

Based on Cubist Systematic Strategies's 13F filing for Q1 2022, filed 16 May 2022.